litlas
Log inCreate account

Ute M. Moll

Active 1980–2025

78
Papers
20,277
Citations
69
h-index
78
i10-index

Citations

Citations per year for Ute M. Moll1980: 8 citations1982: 1 citations1991: 1 citations1992: 10 citations1993: 21 citations1994: 19 citations1995: 19 citations1996: 51 citations1997: 23 citations1998: 47 citations1999: 86 citations2000: 96 citations2001: 114 citations2002: 121 citations2003: 158 citations2004: 171 citations2005: 204 citations2006: 247 citations2007: 197 citations2008: 225 citations2009: 299 citations2010: 250 citations2011: 225 citations2012: 192 citations2013: 219 citations2014: 283 citations2015: 229 citations2016: 233 citations2017: 215 citations2018: 211 citations2019: 607 citations2020: 568 citations2021: 578 citations2022: 402 citations2023: 284 citations2024: 380 citations2025: 209 citations2026: 3 citations1981: no citations, so this year is not shown1983–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,215 citing papers, 26.6% of this breakdownChina: 1,030 citing papers, 12.4% of this breakdownGermany: 488 citing papers, 5.8% of this breakdownUnited Kingdom: 431 citing papers, 5.2% of this breakdownItaly: 409 citing papers, 4.9% of this breakdownFrance: 378 citing papers, 4.5% of this breakdownCanada: 247 citing papers, 3% of this breakdownJapan: 238 citing papers, 2.8% of this breakdownSouth Korea: 182 citing papers, 2.2% of this breakdownAustralia: 178 citing papers, 2.1% of this breakdownIndia: 175 citing papers, 2.1% of this breakdownSpain: 167 citing papers, 2% of this breakdown
0%26.6%Other 26.4%

Institutions

Fields

  • Medicine49.2%
  • Biochemistry, Genetics and Molecular Biology39.7%
  • Immunology and Microbiology4.3%
  • Neuroscience2.2%
  • Agricultural and Biological Sciences1.3%
  • Pharmacology, Toxicology and Pharmaceutics0.7%
  • Other2.6%

Topics

  • Cancer-related Molecular Pathways9.9%
  • Autophagy in Disease and Therapy4.3%
  • Cell death mechanisms and regulation3.4%
  • Epigenetics and DNA Methylation3.1%
  • Ubiquitin and proteasome pathways2.9%
  • RNA modifications and cancer2.7%
  • Other73.7%

Coauthors

All papers

Open in search
  1. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015

    Authors: Lorenzo Galluzzi, José Manuel Bravo‐San Pedro, Ilio Vitale, Stuart A. Aaronson, John Abrams, Dieter Adam, Emad S. Alnemri, Lucia Altucci, David W. Andrews, Margherita Annicchiarico‐Petruzzelli, Eric H. Baehrecke, Nicolás G. Bazán, Mathieu J.M. Bertrand, Katiuscia Bianchi, Mikhail V. Blagosklonny, Klas Blomgren, Christoph Borner, Dale E. Bredesen, Catherine Brenner, Michelangelo Campanella, Eleonora Candi, Francesco Cecconi, Francis Ka-Ming Chan, Navdeep S. Chandel, Emily H. Cheng, Jerry E. Chipuk, John A. Cidlowski, Aaron Ciechanover, Ted M. Dawson, Valina L. Dawson, Vincenzo De Laurenzi, Ruggero De Maria, K-M Debatin, N Di Daniele, Vishva M. Dixit, Brian David Dynlacht, Wafik S. El‐Deiry, Gian María Fimia, Richard A. Flavell, Simone Fulda, Carmen Garrido, M-L Gougeon, Douglas R. Green, Hinrich Gronemeyer, György Hajnóczky, J. Marie Hardwick, Michael O. Hengartner, Hidenori Ichijo, Bertrand Joseph, Philipp J. Jost, Thomas Kaufmann, Oliver Kepp, Daniel J. Klionsky, Richard A. Knight, Sharad Kumar, John J. Lemasters, Beth Levine, Andreas Linkermann, Stuart A. Lipton, Richard A. Lockshin, Carlos López-Otı́n, Enrico Lugli, Frank Madeo, Walter Malorni, J-C Marine, Séamus J. Martin, J-C Martinou, Jan Paul Medema, Pascal Meier, Sonia Melino, Noboru Mizushima, Ute M. Moll, Cristina Muñoz‐Pinedo, Gabriel Núñez, Andrew Oberst, Theocharis Panaretakis, Josef Penninger, Marcus E. Peter, Mauro Piacentini, Paolo Pinton, Jochen H.M. Prehn, Hamsa Puthalakath, Gabriel A. Rabinovich, Kodi S. Ravichandran, Rosario Rizzuto, Cecília M. P. Rodrigues, David C. Rubinsztein, Thomas Rudel, Yufang Shi, H-U Simon, Brent R. Stockwell, György Szabadkai, Stephen W. G. Tait, Ho Lam Tang, N Tavernarakis, Yoshihide Tsujimoto, Tom Vanden Berghe, Peter Vandenabeele, Andreas Villunger, Erwin F. Wagner and 8 more - Cell Death and Differentiation 2014 cited by 1,020

  2. Regulation of autophagy by cytoplasmic p53

    Authors: Ezgi Tasdemir, Maria Chiara Maiuri, Lorenzo Galluzzi, Ilio Vitale, Mojgan Djavaheri‐Mergny, Marcello D’Amelio, Alfredo Criollo, Eugenia Morselli, Changlian Zhu, Francis Harper, Ulf Nannmark, Chrysanthi Samara, Paolo Pinton, José M. Vicencio, Rosa Carnuccio, Ute M. Moll, Frank Madeo, Patrizia Paterlini-Bréchot, Rosario Rizzuto, György Szabadkai, Gérard Pierron, Klas Blomgren, Nektarios Tavernarakis, Patrice Codogno, Francesco Cecconi, Guido Kroemer - Nature Cell Biology 2008 cited by 1,108

  3. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion

    Authors: Ramona Schulz‐Heddergott, Nadine Stark, Shelley J. Edmunds, Jinyu Li, Lena‐Christin Conradi, Hanibal Bohnenberger, Fatih Ceteci, Florian R. Greten, Matthias Dobbelstein, Ute M. Moll - Cancer Cell 2018 cited by 249

  4. p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis

    Authors: Angelina V. Vaseva, Natalie D. Marchenko, Kyungmin Ji, Stella E. Tsirka, Sonja Holzmann, Ute M. Moll - Cell 2012 cited by 741

  5. Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

    Authors: Evguenia M. Alexandrova, Alisha R. Yallowitz, Dun Li, Suheng Xu, Rainer Schulz, David A. Proia, Guillermina Lozano, Matthias Dobbelstein, Ute M. Moll - Nature 2015 cited by 366

  6. The MDM2-p53 interaction.

    Authors: Ute M. Moll, Oleksi Petrenko - 2003 cited by 789

  7. p53 Has a Direct Apoptogenic Role at the Mitochondria

    Authors: Motohiro Mihara, Susan Erster, Alexander Zaika, Oleksi Petrenko, Thomas Chittenden, Petr Pančoška, Ute M. Moll - Molecular Cell 2003 cited by 1,763

  8. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis

    Authors: Dun Li, N D Marchenko, Ute M. Moll - Cell Death and Differentiation 2011 cited by 333

  9. Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis

    Authors: Walter Hanel, N D Marchenko, Suheng Xu, Stephen Yu, Wen-Kai Weng, Ute M. Moll - Cell Death and Differentiation 2013 cited by 288

  10. Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells

    Authors: Dun Li, Natalia Marchenko, Ramona Schulz, Victoria Fischer, Talía Velasco-Hernández, Flaminia Talos, Ute M. Moll - Molecular Cancer Research 2011 cited by 303

  11. The mitochondrial p53 pathway

    Authors: Angelina V. Vaseva, Ute M. Moll - Biochimica et Biophysica Acta (BBA) - Bioenergetics 2008 cited by 635

  12. Epichaperome inhibition targets TP53-mutant AML and AML stem/progenitor cells

    Authors: Bing Z. Carter, Po Yee Mak, Muharrem Müftüoğlu, Wenjing Tao, Baozhen Ke, Jingqi Pei, Andrea Bedoy, Lauren B. Ostermann, Yuki Nishida, Sevinj Isgandarova, Mary Sobieski, Nghi Nguyen, Reid T. Powell, Margarita Martinez-Moczygemba, Clifford Stephan, Mahesh Basyal, Naveen Pemmaraju, Steffen Boettcher, Benjamin L. Ebert, Elizabeth J. Shpall, Barbara Wallner, Robert Morgan, Georgios Ioannis Karras, Ute M. Moll, Michael Andreeff - Blood 2023 cited by 26

  13. Aristolochic acid and the etiology of endemic (Balkan) nephropathy

    Authors: Arthur P. Grollman, Shinya Shibutani, Masaaki Moriya, Frederick W. Miller, Lin Wu, Ute M. Moll, Naomi Suzuki, Andrea Fernandes, Thomas A. Rosenquist, Zvonimir Medverec, Krunoslav Jakovina, Branko Brdar, Neda Slade, Robert J. Turesky, Angela K. Goodenough, Robert Rieger, Mato Vukelić, Bojan Jelaković - National Academy of Sciences, Proceedings of the National Academy of Sciences 2007 cited by 599

  14. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer

    Authors: Rainer Schulz, Felix Streller, Andreas H. Scheel, Jan H. Rüschoff, M-C Reinert, Matthias Dobbelstein, N D Marchenko, Ute M. Moll - Cell Death and Disease 2014 cited by 103

  15. p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state

    Authors: Şerif Şentürk, Zhan Yao, Matthew Camiolo, Brendon M. Stiles, Trushar Rathod, Alice M. Walsh, Alice Nemajerová, Matthew J. Lazzara, Nasser K. Altorki, Adrian R. Krainer, Ute M. Moll, Scott W. Lowe, Luca Cartegni, Raffaella Sordella - National Academy of Sciences, Proceedings of the National Academy of Sciences 2014 cited by 94

  16. p53-Responsive MicroRNAs 192 and 215 Are Capable of Inducing Cell Cycle Arrest

    Authors: Christian Braun, Xin Zhang, Irina Savelyeva, Sonja Wolff, Ute M. Moll, Troels Schepeler, Torben F. Ørntoft, Claus L. Andersen, Matthias Dobbelstein - Cancer Research 2008 cited by 484

  17. Links between mutant p53 and genomic instability

    Authors: Walter Hanel, Ute M. Moll - Journal of Cellular Biochemistry 2011 cited by 219

  18. p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity

    Authors: Sonja Wolff, Susan Erster, Gustavo Palacios, Ute M. Moll - Cell Research 2008 cited by 186

  19. Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target

    Authors: Ramona Schulz‐Heddergott, Ute M. Moll - Cancers 2018 cited by 105

  20. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo

    Authors: Evguenia M. Alexandrova, Safia A Mirza, Sulan Xu, Ramona Schulz‐Heddergott, Natalia Marchenko, Ute M. Moll - Cell Death and Disease 2017 cited by 104

  21. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting

    Authors: Günter Fingerle‐Rowson, Oleksi Petrenko, Christine N. Metz, Thomas G. Forsthuber, Robert A. Mitchell, Ralf Huss, Ute M. Moll, Werner Müller, Richard Bucala - National Academy of Sciences, Proceedings of the National Academy of Sciences 2003 cited by 282

  22. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer

    Authors: Christopher Maximilian Arends, K Kopp, Raphael Hablesreiter, Natàlia Estrada, Friederike Christen, Ute M. Moll, Robert Zeillinger, Wolfgang Schmitt, Jalid Sehouli, Hagen Kulbe, Maximilian Fleischmann, Isabelle Ray‐Coquard, Alain G. Zeimet, Francesco Raspagliesi, Claudio Zamagni, Ignace Vergote, Domenica Lorusso, Nicole Concin, Lars Bullinger, Elena Ioana Braicu, Frédérik Damm - Leukemia 2024 cited by 32

  23. Death Signal-induced Localization of p53 Protein to Mitochondria

    Authors: Natalie D. Marchenko, Alexander Zaika, Ute M. Moll - Journal of Biological Chemistry 2000 cited by 892

  24. MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53

    Authors: Magdalena Wienken, Antje Dickmanns, Alice Nemajerová, Daniela Kramer, Zeynab Najafova, Miriam Weiss, Oleksandra Karpiuk, Moustapha Kassem, Yanping Zhang, Guillermina Lozano, Steven A. Johnsen, Ute M. Moll, Xin Zhang, Matthias Dobbelstein - Molecular Cell 2015 cited by 107